ClinVar Miner

Submissions for variant NM_024675.4(PALB2):c.1424C>G (p.Ser475Ter)

dbSNP: rs886039479
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000255228 SCV000322089 likely pathogenic not provided 2016-06-14 criteria provided, single submitter clinical testing This variant is denoted PALB2 c.1424C>G at the cDNA level and p.Ser475Ter (S475X) at the protein level. The substitution creates a nonsense variant, which changes a Serine to a premature stop codon (TCA>TGA), and is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. Although this variant has not, to our knowledge, been reported in the literature, it is considered likely pathogenic.
Invitae RCV001066196 SCV001231200 pathogenic Familial cancer of breast 2020-02-21 criteria provided, single submitter clinical testing This variant has not been reported in the literature in individuals with PALB2-related conditions. ClinVar contains an entry for this variant (Variation ID: 265326). For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in PALB2 are known to be pathogenic (PMID: 17200668, 24136930, 25099575). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Ser475*) in the PALB2 gene. It is expected to result in an absent or disrupted protein product.
Ambry Genetics RCV002392782 SCV002698658 pathogenic Hereditary cancer-predisposing syndrome 2021-10-18 criteria provided, single submitter clinical testing The p.S475* pathogenic mutation (also known as c.1424C>G), located in coding exon 4 of the PALB2 gene, results from a C to G substitution at nucleotide position 1424. This changes the amino acid from a serine to a stop codon within coding exon 4. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Myriad Genetics, Inc. RCV001066196 SCV004189434 pathogenic Familial cancer of breast 2023-09-08 criteria provided, single submitter clinical testing This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.